Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
BMC Infect Dis ; 12 Suppl 2: S2, 2012.
Article in English | MEDLINE | ID: mdl-23173556

ABSTRACT

Hepatitis C virus (HCV), first recognized as a cause of transfusion-associated acute and chronic hepatitis in 1989, plays a major role as a cause of chronic liver injury, with potential for neoplastic degeneration. It is mainly transmitted by the parenteral route. However, although with lower efficiency, it may be also transmitted by sexual intercourses and by the mother-to-child route. Epidemiological evidence shows that a wave of infection occurred in the 1945-65 period (baby boomers) in western countries. After acute infection, as many as 50-85% of the patients fail to clear the virus resulting in chronic liver infection and/or disease. It is estimated that, on a global scale, about 170 million people are chronically infected with HCV, leading to about 350.000 deaths yearly. Among western countries southern Europe, and particularly Italy, is among the most affected areas. The impact on the public health systems is noteworthy, with high number of hospitalizations due to chronic liver disease, cirrhosis or hepatocellular carcinoma. While waiting for a safe and effective vaccine to be made available, new promising direct-acting antiviral (DAA) drugs offer a better therapeutic scenario than in the past even for the poor responder genotypes 1 and 4, provided that effective screening and care is offered. However, the long and aspecific prodromic period before clinical symptoms develop is a major obstacle to early detection and treatment. Effective screening strategies may target at-risk groups or age specific groups, as recently recommended by the CDC.


Subject(s)
Hepatitis C, Chronic/epidemiology , Carcinoma, Hepatocellular/virology , Global Health , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Humans , Liver Cirrhosis/virology , Liver Neoplasms/virology , Public Health
2.
Dig Liver Dis ; 33(2): 163-72, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11346146

ABSTRACT

BACKGROUND: Effectiveness of combination therapy with standard interferon alpha doses and ribavirin is far from being demonstrated in patients with hepatitis C non responders to interferon alpha monotherapy. Recent kinetic studies revealed that these doses may be suboptimal. AIMS: To find the criteria for optimisation of the interferon dose, to be used in combination with ribavirin in patients with hepatitis C non responders to interferon alpha monotherapy. PATIENTS: Sixty-three patients enrolled in a pilot controlled trial were treated for 6 months with ribavirin ([1000-1200 mg daily) and were randomised to concurrently receive interferon alpha 2b for 6 months at: 3 Million Units thrice weekly [group A (21 patients)], 5 MU thrice weekly [group B (21 patients)] and 5 million units daily [group C (21 patients)]. RESULTS: A sustained virological response was observed in: 1 patient from group A (5%), 2 patients from group B (9%) and 8 patients from group C (38%; p=0.02 vs group A; p=0.03 vs group B). Side-effects were not significantly different between the 3 groups. Multivariate analysis showed that infection by hepatitis C virus genotypes 2 or 3 and interferon alpha dosage of 5 million units daily were independent predictors of sustained response. CONCLUSIONS: These results suggest that higher interferon doses administered daily in combination with ribavirin could be more effective in those patients with hepatitis C who had not responded to interferon alone.


Subject(s)
Antiviral Agents/administration & dosage , Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Ribavirin/administration & dosage , Adolescent , Adult , Analysis of Variance , Biopsy, Needle , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Female , Follow-Up Studies , Hepatitis C, Chronic/pathology , Humans , Logistic Models , Male , Middle Aged , Pilot Projects , Probability , Severity of Illness Index , Statistics, Nonparametric , Treatment Outcome
3.
J Infect Dis ; 183(1): 134-7, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11087200

ABSTRACT

A total of 204 patients with liver biopsy-proven hepatitis C virus (HCV) infection, 84 with and 120 without human immunodeficiency virus (HIV) coinfection, were studied, to evaluate variables possibly associated with the stage of liver fibrosis. All patients were injection drugs users, with a mean age of 32 years and an estimated duration of HCV infection of 12 years. Twenty-four patients (11%) had many fibrous septa with (5%) or without (6%) cirrhosis, 56 (27%) had few fibrous septa, and 124 (60%) had no fibrous septa. In all patients, an association was found between CD4 cell counts <500 cells/mm(3)and the presence of many fibrous septa (odds ratio, 3.2; P=.037), independent of HIV infection and other factors. These results suggest that HIV infection-induced CD4 depletion is independently associated with the severity of liver fibrosis in chronic HCV infection.


Subject(s)
HIV Infections/complications , Hepatitis C, Chronic/complications , Liver Cirrhosis/etiology , Adult , CD4 Lymphocyte Count , Cohort Studies , Disease Progression , Female , HIV Infections/immunology , HIV Seropositivity/complications , HIV Seropositivity/immunology , Humans , Liver Cirrhosis/epidemiology , Liver Cirrhosis/pathology , Male , Odds Ratio , Risk Factors
4.
J Acquir Immune Defic Syndr ; 24(3): 211-7, 2000 Jul 01.
Article in English | MEDLINE | ID: mdl-10969344

ABSTRACT

We undertook this study to assess the association between the various potential causes of liver disease in HIV-seropositive patients and mortality due to liver failure. Three hundred and eight in-hospital deaths were observed from 1987 to December 1995 in a prospectively followed cohort of 1894 HIV-seropositive patients. For each study subject, clinical data were evaluated to assess whether liver failure had substantially contributed to mortality. A case control study nested in the cohort was then performed, which compared demographic and clinical variables observed at enrollment and during follow-up between patients who died for liver disease as the main or concurrent cause of death (cases) and those who died as a result of illness related to AIDS or other causes (controls). Among 308 in-hospital deaths, liver failure was found the cause of death in 35 patients (12%); in 16 cases, it was the primary cause and in 19 cases it was concurrent. Multivariate analysis showed that in-hospital liver-disease-related mortality was independently associated with hepatitis B surface antigen reactivity (odds ratio [OR], 9; 95% confidence interval [CI], 3.8-21.7) and history of alcohol abuse (OR, 2.3; 95% CI, 1-5.2). Prevention and treatment of hepatitis B virus infection and alcohol intake are management priorities in HIV-seropositive patients.


Subject(s)
HIV Infections/complications , Liver Diseases/complications , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/mortality , Adult , Alcoholism/mortality , Antibodies, Viral/analysis , Case-Control Studies , Cohort Studies , Confidence Intervals , DNA, Viral/analysis , Female , Hepatitis B Surface Antigens/analysis , Hepatitis B e Antigens/analysis , Hepatitis B virus/genetics , Hepatitis B virus/isolation & purification , Hepatitis Delta Virus/immunology , Hepatitis, Viral, Human/etiology , Hepatitis, Viral, Human/mortality , Humans , Liver Diseases/immunology , Liver Diseases/mortality , Liver Failure/complications , Liver Failure/mortality , Male , Multivariate Analysis , Risk Factors
5.
J Infect Dis ; 181(6): 2033-6, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10837187

ABSTRACT

In order to assess the relationship between human immunodeficiency virus (HIV) RNA, hepatitis C virus (HCV) RNA, CD4, CD8, and liver enzymes during combination antiretroviral therapy, these parameters were measured in 12 HIV-HCV-coinfected patients (who were naive for antiretrovirals) on the day before and 3, 7, 14, 28, 56, and 84 days after initiating the following treatments: stavudine and lamivudine in all patients, indinavir in 6 patients, and nevirapine in 6 patients. HIV RNA declined rapidly, CD4 cells increased slowly, and CD8 cells and liver enzymes were stable. HCV RNA showed a transient significant increase at days 14 and 21 (7.33+/-0.16 [mean +/- SE] and 7.29+/-0.2 log copies/mL vs. 7+/-0.2 log copies/mL at baseline; P<.05). These changes were similar in both treatment groups. A 2-fold alanine aminotransferase increase was observed in 4 of 12 patients; 4 of 4 patients showed increased HCV RNA. The relationship between HCV RNA increase and HIV RNA decrease indicates virus-virus interference. An HCV RNA increase may cause significant liver damage only in a minority of patients.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/virology , HIV/isolation & purification , Hepacivirus/isolation & purification , Hepatitis C/virology , Liver/physiopathology , Virus Replication , Adult , Alanine Transaminase/blood , Drug Therapy, Combination , HIV Infections/drug therapy , Humans , Male , Pilot Projects , RNA, Viral/analysis
6.
J Clin Lab Anal ; 14(3): 120-4, 2000.
Article in English | MEDLINE | ID: mdl-10797610

ABSTRACT

Early monitoring of HCVRNA during interferon treatment may allow clinicians to obtain important information that could help them to adopt therapeutic decisions in individual cases. The hepatitis C virus infection is highly dynamic and a daily high dose of IFN may induce a decline of viremia of 95+/-10% of baseline value after 24 to 48 hours of treatment. The importance of this early antiviral efficacy has not been understood. We have measured HCVRNA levels in 47 patients with chronic hepatitis C infection during interferon treatment to study HCVRNA kinetics and evaluate the predictive value of the early decay of viremia on the virological response after one month of treatment. Sixty percent of treated patients showed early virological response (EVR) and it was significantly associated with low HCVRNA levels and a genotype other than 1b. Finally, the absence of an 85% decline in HCVRNA levels after 3 days of treatment observed in 11 out of 45 patients (24%) was an absolute and very early predictor of the absence of EVR in the study population.


Subject(s)
Antiviral Agents/administration & dosage , Hepacivirus/genetics , Hepatitis C/drug therapy , Hepatitis C/virology , Interferons/administration & dosage , RNA, Viral/analysis , Adult , Female , Genotype , Hepatitis C/diagnosis , Humans , Male , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity , Viremia/diagnosis , Viremia/drug therapy , Viremia/virology
7.
Ital J Gastroenterol Hepatol ; 31(4): 295-300, 1999 May.
Article in English | MEDLINE | ID: mdl-10425574

ABSTRACT

BACKGROUND: Portal lymphadenopathy is frequently found in inflammatory liver diseases. However, the mechanisms underlying portal lymphadenopathy are unknown. AIMS: To evaluate the prevalence of portal lymphadenopathy in patients with serum anti-hepatitis C Virus antibody reactivity and its relationship to clinical parameters. PATIENTS AND METHODS: The presence of portal lymphadenopathy was evaluated by upper abdominal Ultrasound by the same examiner in 114 patients with anti-hepatitis C Virus reactivity: 56 patients with normal liver enzyme activity and 58 randomly selected patients with increased liver enzyme activity undergoing liver biopsy. Laboratory tests were then performed in all patients the following day. RESULTS: Portal lymph nodes were found in a significantly higher percentage of patients with increased liver enzymes (74%) than in patients with persistently normal liver enzymes (29%: p < 0.01). Aminotransferases, gamma glutamyl transpeptidase levels and the percentage of patients with HCVRNA in serum and histological scores for piecemeal and lobular necrosis were significantly higher in patients showing hepatic lymph nodes. Multivariate analysis showed that only alanine aminotransferase and lobular necrosis were independently related to the presence of hepatic lymph nodes. A significant correlation was found between lymph node size, aminotransferase activity and lobular necrosis. CONCLUSION: Ultrasound-proven portal lymph node enlargement is an indirect sign of hepatocellular damage in patients with positive serum anti-hepatitis C Virus antibodies.


Subject(s)
Hepatitis C Antibodies/analysis , Hepatitis C/diagnostic imaging , Lymph Nodes/diagnostic imaging , Adult , Clinical Enzyme Tests , Cross-Sectional Studies , Female , Hepatitis C/diagnosis , Humans , Liver , Male , Middle Aged , Ultrasonography
8.
Ital J Gastroenterol Hepatol ; 30(4): 391-5, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9789135

ABSTRACT

BACKGROUND: Fifty per cent of patients with chronic hepatitis C, show detectable cryoglobulinaemia, even though most of them do not show cryoglobulinaemia related symptoms. Peripheral neuropathy is present in most of the patients with symptomatic cryoglobulinaemia, where it may be the first clinical manifestation. The prevalence of peripheral neuropathy in patients with hepatitis C and cryoglobulinaemia is unknown. AIMS: To assess the prevalence of peripheral neuropathy in HCV infected patients with symptomatic or asymptomatic detectable cryoglobulinaemia. PATIENTS AND METHODS: Eighty-nine patients with HCV infection and detectable cryoglobulinaemia underwent electrophysiological studies. RESULTS: Electrophysiological evidence of peripheral neuropathy was found in 37% and was significantly associated with: the presence of cryoglobulinaemia syndrome, older age, higher rheumatoid factor reactivity and immunoglobulin M levels and reduced complement C4 activity. However, electrophysiological evidence of peripheral neuropathy was unrelated to cryocrit levels and type of cryoglobulinaemia and was found in 23/68 patients without any symptoms of cryoglobulinaemia other than pain and paresthesia. CONCLUSIONS: These findings suggest that peripheral neuropathy is frequent in patients with hepatitis C and detectable cryoglobulins. Neuropathy was found to be present in 1/3 of patients without other cryoglobulinaemia-related symptoms, thus a direct or indirect role of HCV, independent of cryoglobulinaemia, in the pathogenesis of nerve damage cannot be ruled out.


Subject(s)
Cryoglobulinemia/complications , Hepatitis C/complications , Peripheral Nervous System Diseases/etiology , Peripheral Nervous System Diseases/physiopathology , Age Factors , Chi-Square Distribution , Complement C4/analysis , Electrophysiology , Female , Humans , Immunoglobulins/analysis , Male , Middle Aged , Peripheral Nervous System Diseases/epidemiology , Prevalence , Prospective Studies , Rheumatoid Factor/analysis , Statistics, Nonparametric
9.
J Hepatol ; 29(1): 45-52, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9696491

ABSTRACT

BACKGROUND/AIMS: Hepatitis delta virus (HDV) coinfection is frequent in patients infected with human immunodeficiency virus (HIV), and it may cause death independently of the development of full-blown AIDS. In order to evaluate the efficacy and tolerability of interferon alpha in the treatment of hepatitis delta in HIV-infected patients, and to compare them with those observed in anti-HIV-seronegative patients, we carried out an open uncontrolled trial on 21 HIV-uninfected and 16 HIV-infected patients without severe immunodeficiency. METHODS: All patients were treated with recombinant interferon alpha 2b (IFN) at doses of 10 million units thrice weekly for 6 months, and 6 million units thrice weekly for an additional 6 months. Patients showing alanine transaminase activity values persistently reduced by at least 50% from basal values received an additional 1-year course of 3 million units thrice weekly. RESULTS: Alanine aminotransferase normalization was observed in 19% of HIV-infected and 14% of HIV-uninfected subjects during the first year; in 12% of HIV-infected and in 9% of HIV-uninfected patients during the second year. Twenty-five percent of HIV-infected and 14% of HIV-uninfected patients stopped IFN because of poor compliance or side effects. Two years after stopping interferon treatment, one anti-HIV-seropositive and two anti-HIV-seronegative patients showed complete persistent biochemical, virological and histologic remission. CONCLUSIONS: Long-term efficacy and toxicity of IFN treatment seem not to be different in HIV-infected and -uninfected patients with delta hepatitis; given the overall poor rate of long-term response, IFN treatment could be considered only in immunocompetent HIV-HDV-coinfected patients, strictly selected because of rapidly evolving liver disease.


Subject(s)
Antiviral Agents/therapeutic use , HIV Infections/complications , Hepatitis D, Chronic/complications , Hepatitis D, Chronic/drug therapy , Interferon-alpha/therapeutic use , Adult , Alanine Transaminase/blood , Biopsy , Female , Hepatitis Antibodies/blood , Hepatitis B/complications , Hepatitis C/complications , Hepatitis D, Chronic/pathology , Humans , Interferon alpha-2 , Male , Recombinant Proteins , Remission Induction
SELECTION OF CITATIONS
SEARCH DETAIL
...